Research programme: NCAM agonists - ENKAM Pharmaceuticals

Drug Profile

Research programme: NCAM agonists - ENKAM Pharmaceuticals

Alternative Names: Dennexin; Fibroblast growth factor (FGF) receptor agonists - ENKAM; NCAM mimetic peptides; NCAM mimetics; P2; P2-peptide; Plannexin; TBI therapeutics - ENKAM; Traumatic brain injury therapeutics - ENKAM

Latest Information Update: 28 May 2011

Price : $50

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Fibroblast growth factor receptor agonists; Neural cell adhesion molecule agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Brain injuries

Most Recent Events

  • 27 May 2011 Preclinical development is ongoing in Denmark
  • 07 Nov 2007 Pharmacodynamics data from a preclinical trial presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 03 May 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top